DEA revises opioid scheduling notices while existing controls remain
Oct 11, 2026 edition · GC-2026-0288 · Published 2026-10-11 · Version 3 · Proposed
DOJ describes revised scheduling notices following HHS recommendations. The October 9 announcement distinguishes proposed 7-OH/MGPI thresholds from controls already governing three related substances.
What happened
DOJ says DEA will reissue its MGM-15/MGM-16 notice without changing that approach and issue a new 7-OH/MGPI notice using thresholds distinguishing trace botanical levels from concentrated products. These are announced notices and recommendations, rather than the new scheduling order.
HHS recommends Schedule I treatment if either 7-OH or MGPI, or their combined amount, exceeds 1 mg/g in solids or 1 mg/mL in liquids, or the mitragynine-to-listed-substance ratio is below 100:1. DOJ says existing MGPI/MGM-15/MGM-16 controls continue through the new 30-day notice period until a new order, while no temporary 7-OH order has issued.
Scope and timing
- Authority status
- Proposed
- Applicability
- Operationally relevant
- Audience
- Health systems, Provider networks
- Jurisdiction
- Federal
Why it matters
MGPI, MGM-15 and MGM-16 remain temporarily Schedule I under August 26 controls. DEA had not issued a temporary scheduling order for 7-OH; an announced notice is not that order.
Recommended action
Pharmacy and legal should monitor the actual notices and subsequent orders; preserve existing controls and separate substance-specific status.
Sources
- DOJ updated emergency scheduling announcementOfficial · DOJ and DEA · 2026-10-09 · Source review 2026-10-11
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Compliance Sweep report →